Study Finds Gaps in Lichen Planus Screening and Treatment Among U.S. Dermatologists

A new cross-sectional study from George Washington University shows significant variability in how U.S. dermatologists diagnose and manage lichen planus, according to a news release.

Surveying over 400 board-certified dermatologists, the study researchers found inconsistent screening practices and wide variation in treatment approaches. Despite known associations between lichen planus and systemic conditions, screening for common comorbidities such as hypertension, anxiety, and depression was often overlooked. Conversely, hepatitis C—an infrequent trigger—was more commonly screened.

Treatment practices also diverged from evidence-based recommendations. While most dermatologists reported prescribing topical corticosteroids, fewer used systemic immunosuppressants or phototherapy, despite demonstrated efficacy. The study also identified widespread unawareness of the lack of FDA-approved therapies for the condition.

The authors said the results highlight the need for clearer diagnostic protocols and treatment guidelines to improve consistency and quality of care.

“These findings underscore the absence of standardized, evidence-based guidelines for lichen planus care,” said Adam Friedman, MD, professor and chair of dermatology at the GW School of Medicine and Health Sciences, in the press release. “Practitioners are often left to rely on training background and personal experience, leading to wide variations in care and, ultimately, potential disparities in patient outcomes.”

The findings were published in Dermatology and Therapy.